Filibuvir

Filibuvir
Clinical data
Other names	PF-00868554
Routes of; administration	Oral
ATC code	none;
Legal status
Legal status	Development terminated;
Identifiers
	IUPAC name (2R)-2-cyclopentyl-2-[2-(2,6-diethylpyridin-4-yl)ethyl]-5-[(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-3H-pyran-6-one;
JSmol)	Interactive image;
	SMILES CCC1=CC(=CC(=N1)CC)CC[C@@]2(CC(=C(C(=O)O2)CC3=NN4C(=CC(=NC4=N3)C)C)O)C5CCCC5;
	InChI InChI=1S/C29H37N5O3/c1-5-22-14-20(15-23(6-2)31-22)11-12-29(21-9-7-8-10-21)17-25(35)24(27(36)37-29)16-26-32-28-30-18(3)13-19(4)34(28)33-26/h13-15,21,35H,5-12,16-17H2,1-4H3/t29-/m1/s1; Key:SLVAPEZTBDBAPI-GDLZYMKVSA-N;

Filibuvir (also known as PF-00868554, PF-868554) was a non-nucleoside orally available

NS5B inhibitor developed by Pfizer for the treatment of hepatitis C. It binds to the non-catalytic Thumb II allosteric pocket of NS5B viral polymerase and causes a decrease in viral RNA synthesis. It is a potent and selective inhibitor, with a mean IC50 of 0.019 μM against genotype 1 polymerases.^[2] Several filibuvir-resistant mutations have been identified, M423 being the most common that occurred after filibuvir monotherapy.^[3] It was intended to be taken twice-daily.^[4]

Its investigation was discontinued in February 2013 due to strategic reasons.[5]^[6]

References

^ "Pfizer Halts Development of Hepatitis C Drug Filibuvir: Report". FirstWorld Pharma. Doctor's Guide Publishing Limited. Retrieved 5 December 2015.
PMID 19307358
.

PMID 24452008
.

PMID 21154154
.

^ Loftus P (8 March 2013). "Pfizer Stops Developing Hepatitis C Drug". The Wall Street Journal. Dow Jones & Company, Inc. Retrieved 5 December 2015.

S2CID 39936873
.

4A
protease inhibitors (–previr)

Asunaprevir

Boceprevir^‡

Ciluprevir^§

Danoprevir^†

Faldaprevir^‡

Glecaprevir

Grazoprevir

Narlaprevir

Paritaprevir

Simeprevir

Sovaprevir^†

Telaprevir^‡

Vaniprevir

Vedroprevir^§

Voxilaprevir

NS5A
inhibitors (–asvir)

Coblopasvir

Daclatasvir^#

Elbasvir

Ledipasvir

Odalasvir^†

Ombitasvir

Pibrentasvir

Ravidasvir^†

Ruzasvir^†

Samatasvir^†

Velpatasvir

NS5B RNA polymerase
inhibitors (–buvir)

Beclabuvir^†

Bemnifosbuvir^†

Dasabuvir^#

Deleobuvir^§

Filibuvir^§

GS-6620^§

IDX-184^§

Setrobuvir^§

Sofosbuvir^#

Tegobuvir^§

TMC-647055^§

Radalbuvir^†

Uprifosbuvir^†

Combination drugs

Elbasvir/grazoprevir

Glecaprevir/pibrentasvir

Ledipasvir/sofosbuvir^#

Ombitasvir/paritaprevir/ritonavir^#

Sofosbuvir/daclatasvir

Sofosbuvir/velpatasvir^#

Sofosbuvir/velpatasvir/voxilaprevir

Hepatitis D

Bulevirtide

Picornavirus

viral entry: Pleconaril^†

Anti-influenza agents

Baloxavir marboxil

Pimodivir^†

Umifenovir

M2 inhibitors (Adapromine

Amantadine

Rimantadine)

neuraminidase inhibitors/release phase (Oseltamivir^#

Zanamivir

Peramivir, Laninamivir^†)

Multiple/general
Interferon

Interferon alfa 2b

Peginterferon alfa-2a^#

Peginterferon alfa-2b^#

3CL protease inhibitors (–trelvir)

Ensitrelvir^†

Lufotrelvir

Nirmatrelvir^† (+ritonavir)^†

Rupintrivir

Simnotrelvir (+ritonavir
^†)

RNA pol inhibitors

CMX521^§

Deuremidevir^†

Favipiravir

Galidesivir^†

GS-441524^§

Remdesivir

MK-608^§

Mericitabine^†

Molnupiravir

NITD008^§

Ribavirin^#

Taribavirin^†

Triazavirin

Valopicitabine^†

Multiple/Unknown/Other

EICAR^§

Merimepodib^§

Moroxydine

Presatovir^†

^#WHO-EM

^‡Withdrawn from market

Clinical trials:
^†Phase III

^§Never to phase III

drug article is a stub. You can help Wikipedia by expanding it.
v
t
e

[1] "Pfizer Halts Development of Hepatitis C Drug Filibuvir: Report". FirstWorld Pharma. Doctor's Guide Publishing Limited. Retrieved 5 December 2015.

[2] PMID 19307358
.

[3] PMID 24452008
.

[4] PMID 21154154
.

[5] Loftus P (8 March 2013). "Pfizer Stops Developing Hepatitis C Drug". The Wall Street Journal. Dow Jones & Company, Inc. Retrieved 5 December 2015.

[6] S2CID 39936873
.

[2]

[3]

[4]

[6]